PDF(Pubmed)
Abstract：
BACKGROUND: An expert panel of Canadian dermatologists was assembled to develop consensus statements regarding the current landscape of topical therapies for plaque psoriasis and the place in therapy of the recently approved fixed-dose combination halobetasol propionate (HP)/tazarotene (TAZ) lotion (HP/TAZ) in the treatment algorithm for plaque psoriasis.
METHODS: A modified nominal group technique, which combined both independent and group input from the expert panel, was used to develop the consensus statements. The expert panel completed surveys to elicit their independent views on the current landscape of topical therapies for plaque psoriasis in Canada. The first expert panel session was held to discuss the existing body of literature and develop draft consensus statements about topical therapies and the place in therapy of HP/TAZ. Independent feedback on the draft consensus statements was solicited from expert panel members prior to another expert panel session where the amended consensus statements were further discussed, edited and, finally, voted on.
RESULTS: The expert panel reached consensus on 20 statements.
CONCLUSIONS: Expert panel members agreed, based on the existing body of literature, that there is a place in therapy for HP/TAZ to address several current unmet treatment needs of patients with plaque psoriasis. Studies have shown that HP/TAZ is an effective and safe first-line treatment for moderate-to-severe plaque psoriasis. Due to its cosmetically pleasing vehicle and once-daily administration, HP/TAZ may improve patient acceptance and treatment adherence.
METHODS: A modified nominal group technique, which combined both independent and group input from the expert panel, was used to develop the consensus statements. The expert panel completed surveys to elicit their independent views on the current landscape of topical therapies for plaque psoriasis in Canada. The first expert panel session was held to discuss the existing body of literature and develop draft consensus statements about topical therapies and the place in therapy of HP/TAZ. Independent feedback on the draft consensus statements was solicited from expert panel members prior to another expert panel session where the amended consensus statements were further discussed, edited and, finally, voted on.
RESULTS: The expert panel reached consensus on 20 statements.
CONCLUSIONS: Expert panel members agreed, based on the existing body of literature, that there is a place in therapy for HP/TAZ to address several current unmet treatment needs of patients with plaque psoriasis. Studies have shown that HP/TAZ is an effective and safe first-line treatment for moderate-to-severe plaque psoriasis. Due to its cosmetically pleasing vehicle and once-daily administration, HP/TAZ may improve patient acceptance and treatment adherence.
摘要：
背景：组建了加拿大皮肤科专家小组，以就斑块状银屑病的局部治疗现状以及最近批准的固定剂量联合丙酸卤倍他扎罗汀（TAZ）洗剂（HP/TAZ）在银屑病斑块治疗算法中的治疗地位达成共识。
方法：改进的名义分组技术，结合了专家小组的独立和小组输入，被用来制定共识声明。专家小组完成了调查，以激发他们对加拿大斑块状银屑病局部治疗现状的独立看法。举行了第一次专家小组会议，讨论了现有的文献，并就局部疗法和HP/TAZ在治疗中的地位制定了共识声明草案。在进一步讨论经修订的协商一致声明的另一次专家小组会议之前，征求了专家小组成员对协商一致声明草案的独立反馈。编辑和,最后,投票。
结果：专家小组就20项声明达成共识。
结论：专家小组成员同意，基于现有的文学体系，HP/TAZ在治疗上有一席之地，可以解决斑块状银屑病患者目前尚未满足的几种治疗需求。研究表明，HP/TAZ是中重度斑块型银屑病的有效和安全的一线治疗方法。由于其美观的载体和每日一次的给药，HP/TAZ可以提高患者的接受度和治疗依从性。
方法：改进的名义分组技术，结合了专家小组的独立和小组输入，被用来制定共识声明。专家小组完成了调查，以激发他们对加拿大斑块状银屑病局部治疗现状的独立看法。举行了第一次专家小组会议，讨论了现有的文献，并就局部疗法和HP/TAZ在治疗中的地位制定了共识声明草案。在进一步讨论经修订的协商一致声明的另一次专家小组会议之前，征求了专家小组成员对协商一致声明草案的独立反馈。编辑和,最后,投票。
结果：专家小组就20项声明达成共识。
结论：专家小组成员同意，基于现有的文学体系，HP/TAZ在治疗上有一席之地，可以解决斑块状银屑病患者目前尚未满足的几种治疗需求。研究表明，HP/TAZ是中重度斑块型银屑病的有效和安全的一线治疗方法。由于其美观的载体和每日一次的给药，HP/TAZ可以提高患者的接受度和治疗依从性。
